Getting on Track in Atopic Dermatitis
An Interactive Educational Journey
Atopic Dermatitis Overview and Pathogenesis
Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts.
Paternoster L, et al. J Allergy Clin Immunol. 2018:141(3):964-971.
Pathogenesis of atopic dermatitis.
Peng W, Novak N. Clin Exp Allergy. 2015;45(3):566-574.
Patient Burden and Comorbidities
Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey.
Eckert L, et al. J Am Acad Dermatol. 2017;77(2):274-279.
Bidirectional relationships between psychological health and dermatological conditions in children.
Ramirez FD, et at. JAMA Pediatr. 2019;173(5):e190025.
Association of atopic dermatitis with sleep quality in children.
Ramirez FD, et at. JAMA Pediatr. 2019;173(5):e190025.
Atopic dermatitis in adults.
Silverberg JI. Med Clin N Am. 2020;104(1):157-176.
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Mental health comorbidity in patients with atopic dermatitis.
Yaghmaie P, et al. J Allergy Clin Immunol. 2013;131(2):428-433.
Management of Atopic Dermatitis
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape.
Boguniewicz M, et al. Ann Allergy Asthma Immunol. 2018;120(1):10-22.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomized controlled phase 3 trials.
Guttman-Yassky E, et al. Lancet. 2021;397(10290):2151-2168.
Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity.
Huang JT, et al. Pediatrics. 2009;123(5):e808-e814.
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H, et al. J Am Acad Dermatol. 2020;82(4):823-831.
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3 randomized, double-blind studies.
Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.
Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial.
Saeki, et al. J Am Acad Dermatol.2021; https://doi.org/10.1016/j.jaad.2021.10.027; in press.
Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial.
Silverberg JI, et al. JAMA Dermatol. 2020;156(8):863-873.
Baracitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Simpson EL, et al. Br J Dermatol. 2020;183(2):242-255.
When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council.
Simpson EL, et al. J Am Acad Dermatol. 2017;77(4):623-633.
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, et al. Br J Dermatol. 2021. 184(3):437-449.
Guidelines
Guidelines of care for the management of atopic dermatitis: part 1. Diagnosis and assessment of atopic dermatitis.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;70(2):338-351.
Guidelines of care for the management of atopic dermatitis: part 2. Management and treatment of atopic dermatitis with topical therapies.
Eichenfield LF, et al. J Am Acad Dermatol. 2014;71(1):116-132.
Guidelines of care for the management of atopic dermatitis: part 3. Management and treatment with phototherapy and systemic agents.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(2):327-349.
Guidelines of care for the management of atopic dermatitis: part 4. Prevention of disease flares and use of adjunctive therapies and approaches.
Sidbury R, et al. J Am Acad Dermatol. 2014;71(6):1218-1233.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(5):657-682.
Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II.
Wollenberg A, et al. J Eur Acad Dermatol Venereol. 2018;32(6):850-878.
Patient Resources
The Society for Pediatric Dermatology
Established in 1975, the mission of the Society for Pediatric Dermatology is to advance the specialty through education and research, to develop new means of treatment, and to provide advocacy in support of pediatric patients with skin, hair, and nail disorders. Informative patient education videos have been developed for patients with atopic dermatitis and their families.
International Eczema Council
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education, and patient/family care.
National Eczema Association
The National Eczema Association is a nonprofit organization founded in 1988 to improve the health and quality of life for individuals with eczema through research, support, and education.
Clinical Assessment Tools
Children’s Dermatology Life Quality Index (CDLQI)
CDLQI is 10-question patient-reported assessment tool designed to measure impact of any skin disease on the lives of children ages 4-16. (Lewis-Jones MS, Finlay AY. Br J Dermatol. 1995;132(6):942-949).
Eczema Area and Severity Index (EASI)
EASI is a clinician assessment tool designed to measure clinical severity of atopic dermatitis. Severity scores can range from 0 (clear) to 72 (very severe). (Hanifin JM, et al. Exp Dermatol. 2001;10(1):11-18).
Investigator Global Assessment (IGA)
The IGA is a clinician assessment strategy designed to provide a snapshot of overall disease severity in dermatologic clinical trials. (Futamura M, et al. J Am Acad Dermatol. 2016;74(2):288-294).
Patient-Oriented Eczema Measure (POEM)
The POEM is a patient-oriented, self-assessed measurement tool for monitoring aspects of atopic dermatitis in routine clinical practice or in the clinical trial setting. (Charman CR, et al. Arch Dermatol. 2004;140(12):1513-1519).
Scoring Atopic Dermatitis (SCORAD)
SCORAD is a clinical tool used to assess the extent and severity of eczema. (Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186(1):23-31.)
Getting on Track in Atopic Dermatitis
An Interactive Educational Journey
| Faculty: | Melinda Gooderham, MSc, MD, FRCPC |
| Release: | 02/04/2022 |
| Expiration: | 02/04/2023 |
